The SFDA Organizes Drug Innovation Conference

The Saudi Food and Drug Authority (SFDA) hosted the Drug Innovation Conference, timed to coincide with World Creativity and Innovation Day. The event, held at the SFDA's headquarters in Riyadh, drew participation from officials representing government authorities, research centers, and universities.

The Chief Executive Officer of the SFDA, H.E. Dr. Hisham S. Aljadhey, reaffirmed in his opening remarks that innovation is fundamental to achieving a resilient pharmaceutical system. He emphasized the crucial role of innovation in enhancing drug safety and fostering scientific advancement. He stated, "The Kingdom of Saudi Arabia is actively shaping its research, regulatory, and industrial frameworks in this pursuit, aligning with the Health Sector Transformation Program's objectives, a key component of Saudi Vision 2030."

Dr. Aljadhey further elaborated that the SFDA, in collaboration with its public and private sector partners, “is committed to cultivating an environment of innovation and empowering national industries to develop innovative and breakthrough drug products.”

The conference gathered significant attendance from representatives of the Ministry of Health, the Ministry of Industry and Mineral Resources, the Ministry of Investment, the Saudi Authority for Intellectual Property, the Research, Development, and Innovation Authority, the Saudi National Institute of Health, and King Saud University. This broad participation highlighted the conference's significance in examining the trajectory of drug innovation both domestically and internationally.

The sessions delved into the supportive role of government authorities in pharmaceutical innovation, emerging trends in drug development, the integration of artificial intelligence in therapeutic discovery, and the regulatory and clinical considerations for novel treatments. Furthermore, initiatives by the World Health Organization (WHO) in this domain were examined.

Through this conference, the SFDA seeks to amplify its support for research and innovation, advance its goal of becoming a global leader in ensuring the quality and safety of innovative pharmaceutical products, and showcase its ongoing efforts in alignment with its Fourth Strategy.